Before the operation, not instead of it
What the weight-loss-jab headlines miss at the point of lung surgery

The weight-loss-jab headlines argue over whether the drug treats lung cancer; the question that changes what happens on my operating list is a different one, and it is the one being missed.

Reviewing a single afternoon's clinic letters not long ago, I noticed two patients taking a GLP-1 drug — one for diabetes, one for weight loss. A year ago that would have been worth a remark; now it is unremarkable, and becoming more so. These medicines — the diabetes and weight-loss injections sold as Ozempic, Wegovy and others — are arriving in thoracic clinics faster than the evidence about them has matured. A study presented at this year's American Society of Clinical Oncology (ASCO) meeting linked them to slower cancer progression, lung cancer among them. The coverage that followed asked whether these drugs prevent cancer, or treat it. Both are fair questions for an oncologist. Neither is the question a surgeon meets. By the time a patient with a resectable lung cancer reaches my clinic, the drug's relevance is not whether it shrinks the tumour. It is what it does on the morning of the operation — and whether the headline tempts anyone to put the operation off.

Should a patient stop a GLP-1 before lung surgery?

This is the practical question, and the one with a settled answer. GLP-1 receptor agonists slow the rate at which the stomach empties, which raises a genuine concern at the start of an anaesthetic: a stomach less empty than the fasting time suggests, and a risk of aspiration. The early instinct, particularly in the United States, was to stop these drugs before surgery. The UK position, set out in a 2025 multi-society consensus statement in Anaesthesia, is more measured — continue the drug, assess each patient's risk, and use anaesthetic techniques that reduce the aspiration risk, rather than withholding it. (The related SGLT2 inhibitors, a different class, are treated differently and omitted on the day before and the day of surgery.) The delay in gastric emptying is established; the evidence that it translates into actual aspiration during surgery is weaker. For most patients on the list, then, the answer is not stop, but tell us, so we can plan. That is the conversation worth having before an operation — not whether to cancel it.

What did the ASCO study actually show?

Less than the headlines implied, and in a narrower group than the word “lung cancer” suggests. The analysis — an ASCO 2026 conference abstract, not yet peer-reviewed — used real-world records from 10,225 patients who started a GLP-1 receptor agonist after a cancer diagnosis, each matched to a similar patient taking an older diabetes drug, a DPP-4 inhibitor. Across seven cancers, progression to stage IV was lower on the GLP-1 in four of them, including non-small-cell lung cancer, where 10% progressed against 22% on the comparator; higher levels of the GLP-1 receptor within the tumour tracked with longer survival. The signal is worth taking seriously. But it is observational: the two groups may differ in ways the matching cannot capture, patients who are prescribed and stay on these drugs tend to be more closely followed, and the comparison was against another diabetes drug — not against no treatment, still less against an operation. The study's own lead author described it as early evidence that further work is worth doing. That is the right register.

Does a weight-loss jab prevent lung cancer?

For the lung, the honest answer is that it has not been shown. A separate study in JAMA Oncology this year, following tens of thousands of adults with obesity, found GLP-1 use associated with a lower overall risk of cancer — but the reductions were concentrated in hormonally driven cancers such as endometrial, ovarian and meningioma. For lung cancer specifically, the association did not reach statistical significance. The lung signal, such as it is, sits in progression, not prevention. Conflating the two is how a cautious finding becomes an overstated headline.

Is it a substitute for the operation?

No — and from where I sit this is the point that matters most. For a lung cancer that can be removed, the operation remains the treatment that changes the outcome. The risk I think about is a quiet one: that someone with an operable cancer found early reads that a weight-loss drug “cuts progression” and wonders whether surgery can wait, or be avoided altogether. Nothing in the ASCO data supports that. It looked at people who already had cancer and remained on standard treatment; it did not test a drug against an operation, and was never designed to. A drug that may slow a cancer in a retrospective database is not an alternative to removing an early one. Where surgery is the right treatment, the delay is the harm — not the drug.

The headlines fuse three different questions: does the drug prevent lung cancer, does it slow it, and what should happen when a patient who takes it needs an operation. They have different answers — not shown, perhaps, and a clear plan — and only the last is one a surgeon owns. These drugs are now part of the clinical picture for a large and growing number of patients, many of whom will, at some point, face an operation. The useful contribution from the surgical side is not to adjudicate the cancer biology, which others are better placed to do, but to keep the operating-table question in view: manage the drug, keep the conversation open, and make sure a treatable cancer is not quietly left in place while the evidence catches up.

← Back to the Journal